Validation of a Genomic Classifier in the NRG Oncology/ RTOG 0521 Phase Ill Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer

被引：0

作者：

Phillips, R. ^{[1
]}

Proudfoot, J. ^{[2
]}

Davicioni, E. ^{[2
,3
]}

Spratt, D. E. ^{[4
]}

Feng, F. Y. ^{[5
]}

Simko, J. ^{[6
]}

Den, R. B. ^{[7
]}

Pollack, A. ^{[8
]}

Rosenthal, S. A. ^{[9
]}

Sartor, O. ^{[10
]}

Sweeney, C. ^{[11
]}

Attard, G. ^{[12
]}

Patel, S. I. ^{[13
]}

Hall, W. A. ^{[14
]}

Efstathiou, J. A. ^{[15
]}

Shah, A. B. ^{[16
]}

Hoffman, K. E. ^{[17
]}

Pugh, S. ^{[18
]}

Sandler, H. M. ^{[19
]}

Tran, P. T. ^{[20
]}

机构：

[1] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA

[2] Veracyte Inc, San Diego, CA USA

[3] Univ Hosp Seidman Canc Ctr, Dept Radiat Oncol, Cleveland, OH USA

[4] Case Western Reserve Univ, Cleveland, OH USA

[5] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA

[6] UCSF, San Francisco, CA USA

[7] Thomas Jefferson Univ, Dept Radiat Oncol, Sidney Kimmel Med Coll & Ctr Canc, Philadelphia, PA USA

[8] Miami Univ, Dept Radiat Oncol, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Sutter Med Grp & Canc Ctr, Sacramento, CA USA

[10] Tulane Univ, New Orleans, LA USA

[11] South Australian Immunogen Canc Inst, Adelaide, SA, Australia

[12] Inst Canc Res, London, England

[13] Univ Alberta, Div Radiat Oncol, Edmonton, AB, Canada

[14] Med ColI Wisconsin, Dept Radiat Oncol, Milwaukee, WI USA

[15] Harvard Med Sch, Dept Radiat Oncol, Boston, MA USA

[16] York Canc Ctr, York, PA USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Breast Radiat Oncol, Houston, TX USA

[18] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA

[19] Cedars Sinai Med Ctr, Los Angeles, CA USA

[20] Univ Maryland, Dept Radiat Oncol, Sch Med, Baltimore, MD USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

158

引用

页码：S34 / S35

页数：2

共 50 条

[31] The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (Updated)
Hall, W. A.
Karrison, T. G.
Rosenthal, S. A.
Amin, M.
Gomella, L. G.
Purdy, J. A.
Sartor, O.
Michalski, J. M.
Garzotto, M.
Bergom, C.
Jani, A.
Lawton, C. A. F.
Simko, J.
Moore, J.
Gore, E. M.
Lee, W. R.
Nguyen, P. L.
Danielson, B. L.
Sandler, H. M.
Feng, F. Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E562 - E563
[32] SINGLE PHASE IMRT TECHNIQUE AND ANDROGEN SUPPRESSION (AS) FOR LOCALIZED HIGH-RISK PROSTATE CANCER, PHASE I/II.
Byrnes, R.
Ghaly, M.
Satchwill, K.
Giorello, C.
Graham, L.
Serviss, D.
RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S340 - S340
[33] The First Report of NRG Oncology/RTOG 0622: A Phase 2 Trial of Samarium 153 Followed by Salvage Irradiation in High-Risk Nonmetastatic Prostate Cancer After Prostatectomy
Valicenti, R. K.
Pugh, S. L.
Trabulsi, E.
Sartor, O.
Girvigian, M. R.
Rosenthal, S. A.
Shaves, M.
Schallenkamp, J. M.
Hoffman-Censits, J.
Sandler, H. M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S134 - S134
[34] Phase I trial of total androgen blockade, weekly docetaxel, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma
Ramey, Stephen J.
Golshayan, Ali Reza
Keane, Thomas E.
Kraft, Andrew S.
Chaudhary, Uzair Bashir
Marshall, David T.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[35] Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate Adenocarcinoma
Marshall, David T.
Ramey, Stephen
Golshayan, Ali-Reza
Keane, Thomas E.
Kraft, Andrew S.
Chaudhary, Uzair
CLINICAL GENITOURINARY CANCER, 2014, 12 (02) : 80 - 86
[36] Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials
Nguyen, P.
Liu, V.
Proudfoot, J. A.
Davicioni, E.
Liu, Y.
Dal Pra, A.
Spratt, D. E.
Sandler, H. M.
Efstathiou, J. A.
Lawton, C.
Simko, J. P.
Rosenthal, S.
Zeitzer, K.
Mendez, L.
Hartford, A.
Hall, W.
Desai, A.
Pugh, S.
Tran, P. T.
Feng, F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1172 - S1173
[37] Re: Validation of a 22-Gene Genomic Classifier in Patients with Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial
Taneja, Samir S.
JOURNAL OF UROLOGY, 2021, 206 (05): : 1330 - 1331
[38] Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
B Mellado
A Font
A Alcaraz
L A Aparicio
F J G Veiga
J Areal
E Gallardo
N Hannaoui
J R M Lorenzo
A Sousa
P L Fernandez
P Gascon
British Journal of Cancer, 2009, 101 : 1248 - 1252
[39] Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
Mellado, B.
Font, A.
Alcaraz, A.
Aparicio, L. A.
Veiga, F. J. G.
Areal, J.
Gallardo, E.
Hannaoui, N.
Lorenzo, J. R. M.
Sousa, A.
Fernandez, P. L.
Gascon, P.
BRITISH JOURNAL OF CANCER, 2009, 101 (08) : 1248 - 1252
[40] Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high risk localized prostate cancer (HRLCaP)
McKenzie, M.
Chi, K.
Neville, A.
Ellard, S.
Baerg, B.
Ruether, D.
Winquist, E.
Segal, R.
Attwell, A.
Lukka, H.
RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S10 - S11

← 1 2 3 4 5 →